Cécile Maupas Appointed Senior VP & CCO at Veranova

Veranova has appointed Cécile Maupas as Senior Vice President and Chief Commercial Officer, marking her role in leading business development, marketing, project management, commercial operations, and product management. Her arrival coincides with Veranova's $30 million expansion of antibody-drug conjugate (ADC) and highly potent compound capabilities at its Devens, MA facility.

Cécile brings a wealth of experience in contract development and manufacturing organizations (CDMO) and the pharmaceutical sector. She holds a B.A. and Master's in Biochemistry from the University of Paris and began her career at GE Healthcare Life Sciences, where she progressed through sales management roles. At Novasep, she focused on expanding the biopharma CDMO business with a specialization in monoclonal antibodies, ADCs, and viral vectors. Her tenure at Pierre Fabre and Sanofi Active Ingredient Solutions further enhanced her expertise in biotech drug substances, including ADCs, small molecules, peptides, oligonucleotides, and high potency active pharmaceutical ingredients (HPAPI).

Veranova's CEO, Mike Riley, expressed enthusiasm about Cécile's appointment, highlighting her proven track record in business growth and transformation. The company looks forward to leveraging her leadership to advance its global strategy, aiming to excel in CDMO services and deliver impactful solutions for partners and patients alike.